• Something wrong with this record ?

Comparative efficacy of different acute reperfusion therapies for acute ischemic stroke: a comprehensive benefit-risk analysis of clinical trials

G. Tsivgoulis, J. Alleman, AH. Katsanos, AD. Barreto, M. Kohrmann, PD. Schellinger, CA. Molina, AV. Alexandrov,

. 2014 ; 4 (6) : 789-97. [pub] 20140911

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't, Review

Persistent link   https://www.medvik.cz/link/bmc15031750

BACKGROUND: Numerous acute reperfusion therapies (RPT) are currently investigated as potential new therapeutic targets in acute ischemic stroke (AIS). We conducted a comprehensive benefit-risk analysis of available clinical studies assessing different acute RPT, and investigated the utility of each intervention in comparison to standard intravenous thrombolysis (IVT) and in relation to the onset-to-treatment time (OTT). METHODS: A comprehensive literature search was conducted to identify all available published, peer-reviewed clinical studies that evaluated the efficacy of different RPT in AIS. Benefit-to-risk ratio (BRR), adjusted for baseline stroke severity, was estimated as the percentage of patients achieving favorable functional outcome (BRR1, mRS score: 0-1) or functional independence (BRR2, mRS score: 0-2) at 3 months divided by the percentage of patients who died during the same period. RESULTS: A total of 18 randomized (n = 13) and nonrandomized (n = 5) clinical studies fulfilled our inclusion criteria. IV therapy with tenecteplase (TNK) was found to have the highest BRRs (BRR1 = 5.76 and BRR2 = 6.82 for low-dose TNK; BRR1 = 5.80 and BRR2 = 6.87 for high-dose TNK), followed by sonothrombolysis (BRR1 = 2.75 and BRR2 = 3.38), while endovascular thrombectomy with MERCI retriever was found to have the lowest BRRs (BRR1 range, 0.31-0.65; BRR2 range, 0.52-1.18). A second degree negative polynomial correlation was detected between favorable functional outcome and OTT (R (2) value: 0.6419; P < 0.00001) indicating the time dependency of clinical efficacy of all reperfusion therapies. CONCLUSION: Intravenous thrombolysis (IVT) with TNK and sonothrombolysis have the higher BRR among investigational reperfusion therapies. The combination of sonothrombolysis with IV administration of TNK appears a potentially promising therapeutic option deserving further investigation.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15031750
003      
CZ-PrNML
005      
20160309105209.0
007      
ta
008      
151005s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/brb3.279 $2 doi
035    __
$a (PubMed)25365799
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Tsivgoulis, Georgios $u Department of Neurology, University of Tennessee Health Science Center Memphis, Tennessee ; Second Department of Neurology, "Attikon Hospital", School of Medicine, University of Athens Athens, Greece ; International Clinical Research Center, St. Anne's University Hospital in Brno Brno, Czech Republic.
245    10
$a Comparative efficacy of different acute reperfusion therapies for acute ischemic stroke: a comprehensive benefit-risk analysis of clinical trials / $c G. Tsivgoulis, J. Alleman, AH. Katsanos, AD. Barreto, M. Kohrmann, PD. Schellinger, CA. Molina, AV. Alexandrov,
520    9_
$a BACKGROUND: Numerous acute reperfusion therapies (RPT) are currently investigated as potential new therapeutic targets in acute ischemic stroke (AIS). We conducted a comprehensive benefit-risk analysis of available clinical studies assessing different acute RPT, and investigated the utility of each intervention in comparison to standard intravenous thrombolysis (IVT) and in relation to the onset-to-treatment time (OTT). METHODS: A comprehensive literature search was conducted to identify all available published, peer-reviewed clinical studies that evaluated the efficacy of different RPT in AIS. Benefit-to-risk ratio (BRR), adjusted for baseline stroke severity, was estimated as the percentage of patients achieving favorable functional outcome (BRR1, mRS score: 0-1) or functional independence (BRR2, mRS score: 0-2) at 3 months divided by the percentage of patients who died during the same period. RESULTS: A total of 18 randomized (n = 13) and nonrandomized (n = 5) clinical studies fulfilled our inclusion criteria. IV therapy with tenecteplase (TNK) was found to have the highest BRRs (BRR1 = 5.76 and BRR2 = 6.82 for low-dose TNK; BRR1 = 5.80 and BRR2 = 6.87 for high-dose TNK), followed by sonothrombolysis (BRR1 = 2.75 and BRR2 = 3.38), while endovascular thrombectomy with MERCI retriever was found to have the lowest BRRs (BRR1 range, 0.31-0.65; BRR2 range, 0.52-1.18). A second degree negative polynomial correlation was detected between favorable functional outcome and OTT (R (2) value: 0.6419; P < 0.00001) indicating the time dependency of clinical efficacy of all reperfusion therapies. CONCLUSION: Intravenous thrombolysis (IVT) with TNK and sonothrombolysis have the higher BRR among investigational reperfusion therapies. The combination of sonothrombolysis with IV administration of TNK appears a potentially promising therapeutic option deserving further investigation.
650    _2
$a ischemie mozku $x terapie $7 D002545
650    _2
$a klinické zkoušky jako téma $7 D002986
650    _2
$a fibrinolytika $x terapeutické užití $7 D005343
650    _2
$a lidé $7 D006801
650    _2
$a reperfuze $x metody $7 D015424
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a cévní mozková příhoda $x terapie $7 D020521
650    _2
$a tkáňový aktivátor plazminogenu $x terapeutické užití $7 D010959
650    _2
$a ultrazvuková terapie $x metody $7 D014464
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Alleman, John $u Cerevast Therapeutics, Inc. Redmond, Washington. $7 gn_A_00004434
700    1_
$a Katsanos, Aristeidis H $u Department of Neurology, University of Ioannina Ioannina, Greece.
700    1_
$a Barreto, Andrew D $u Department of Neurology, University of Texas-Houston Medical School Houston, Texas.
700    1_
$a Kohrmann, Martin $u Department of Neurology, University Clinic at Erlangen Erlangen, Germany.
700    1_
$a Schellinger, Peter D $u Departments of Neurology and Neurogeriatry, Johannes Wesling Clinic Minden Minden, Germany.
700    1_
$a Molina, Carlos A $u Neurovascular Unit, Department of Neurology, Hospital Vall d'Hebron Barcelona, Spain.
700    1_
$a Alexandrov, Andrei V $u Department of Neurology, University of Tennessee Health Science Center Memphis, Tennessee. $7 gn_A_00003944
773    0_
$w MED00188000 $t Brain and behavior $x 2162-3279 $g Roč. 4, č. 6 (2014), s. 789-97
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25365799 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20151005 $b ABA008
991    __
$a 20160309105225 $b ABA008
999    __
$a ok $b bmc $g 1092626 $s 914876
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 4 $c 6 $d 789-97 $e 20140911 $i 2162-3279 $m Brain and behavior $n Brain Behav $x MED00188000
LZP    __
$a Pubmed-20151005

Find record

Citation metrics

Archiving options